A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

NCT03053440 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Waldenström's Macroglobulinemia

Interventions

DRUG: BGB-3111
DRUG: Ibrutinib

Sponsor

BeiGene